Veterinary Notice - TBA Welcomes Resumption In Supply Of Artervac Vaccine
The Artervac equine viral arteritis (EVA) vaccine is now back in stock at wholesalers following a two-and-a-half-year hiatus in supply, which meant that previously vaccinated British-based thoroughbred stallions had lapsed vaccination status for EVA, and some stallions more recently retired to stud had not yet had the opportunity to be vaccinated. This necessitated additional blood tests for EVA from mares during the 2023 and 2024 breeding seasons, to ensure the continued freedom from this disease that the domestic thoroughbred population maintains, due to close adherence to the HBLB International Codes of Practice.
The TBA thanks all breeders for their patience and understanding of these additional health testing requirements during this period. Whilst the ideal scenario would be for consistent and continued production of Artervac by Zoetis, in reality there is limited demand for the vaccine beyond the thoroughbred population, meaning its commercial viability may be uncertain.
During the absence in supply of Artervac, the TBA has been working with the Veterinary Medicines Directorate (VMD) to try and obtain an import licence for the modified live EVA vaccine, Arvac (as used in Kentucky, and more recently in Ireland). A protocol for the isolation of stallions following a primary dose of Arvac is being negotiated with the APHA and a framework agreed in principle may safeguard the thoroughbred industry in case of any future disruption in availability of Artervac.
Equine Infectious Disease Surveillance (EIDS), partly funded by the thoroughbred industry and based at Cambridge University, has adapted their guidance for lapsed [Artervac] vaccinated stallions to support veterinarians and stud managers with commencing new courses i.e. testing linked to re-starting the primary course, which will be necessary due to the length of time the vaccine has not been available. The guidance is available on the EIDS website via the following link: https://equinesurveillance.org/landing/resources/June2025-EIDS-Artervac-Vaccine-Update.pdf.
If you have any questions or feedback relating to EVA, Artervac or Arvac then please e-mail [email protected] who will identify the most appropriate expert to assist you.
If you have any questions, please call the TBA office on 01638 661 321.